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Chronic glucocorticoid treatment 
induces hepatic lipid accumulation 
and hyperinsulinaemia in part 
through actions on AgRP neurons
Erika Harno1,4*, Charlotte Sefton1, Jonathan R. Wray1, Tiffany‑Jayne Allen1, Alison Davies1, 
Anthony P. Coll2 & Anne White3,4*
Glucocorticoids (GCs) are widely prescribed anti‑inflammatory medicines, but their use can lead 
to metabolic side‑effects. These may occur through direct actions of GCs on peripheral organs, but 
could also be mediated by the hypothalamic AgRP neurons, which can increase food intake and 
modify peripheral metabolism. Therefore, the aim of this study was to examine the metabolic effects 
of chronic treatment with the GC corticosterone (Cort, 75 μg/ml in drinking water) in mice lacking 
the glucocorticoid receptor (GR) on AgRP neurons. Female AgRP‑GR KO mice had delayed onset of 
Cort‑induced hyperphagia. However, AgRP‑GR KO had little impact on the increased body weight 
or adiposity seen with 3 weeks Cort treatment. Cort caused hepatic steatosis in control mice, but 
in Cort treated female AgRP‑GR KO mice there was a 25% reduction in liver lipid content and lower 
plasma triglycerides. Additionally, Cort treatment led to hyperinsulinaemia, but compared to controls, 
Cort‑treated AgRP‑GR KO mice had both lower fasting insulin levels and lower insulin levels during a 
glucose tolerance test. In conclusion, these data indicate that GCs do act through AgRP neurons to 
contribute, at least in part, to the adverse metabolic consequences of chronic GC treatment.
Glucocorticoids (GCs) are widely prescribed medicines for the treatment of inflammatory disorders including 
arthritis, asthma and some malignancies, with 12% of patients in England being prescribed oral GCs in  20181. 
Chronic treatment of patients with GCs, especially at high doses, is associated with a plethora of side effects. 
These include body weight  gain2, central obesity, insulin resistance and an increased risk of developing diabetes 
 mellitus3. While some side effects such as osteoporosis can be reduced with the use of prophylactic agents, at 
present there are no similar treatments for the metabolic effects. Therefore, delineating the mechanisms of the 
metabolic effects from those of the beneficial anti-inflammatory effects, could lead to the design of alternative 
GCs or co-therapies to reduce the metabolic side effects.
Model organisms have proven to be useful to further understand the mechanisms that underpin the effect 
of exogenous GCs on body weight and body composition. Although there are recognised differences in study 
outcome depending upon rodent species and the type and formulation of GC  used4–7, data from murine models 
have highlighted that the increase in food intake and altered adiposity often seen with GC therapy are likely to 
be mediated via actions both in the brain and at the level of peripheral tissues. For example, GCs are recognised 
to act in the arcuate nucleus of the hypothalamus to induce  hyperphagia8–11, leading to increased body weight. 
Peripherally, GCs act on adipose tissue and can regulate de novo lipogenesis and induce lipolysis depending 
on the physiological or pharmacological context (reviewed in Macfarlane et al.  200812). This can cause excess 
adiposity or adipose tissue remodelling and fat redistribution  respectively8–13. Furthermore, in brown adipose 
tissue (BAT), GCs are known to cause lipid infiltration, as well as reduce the expression of markers of ther-
mogenesis, such as UCP-19,14. While the effects of chronic GCs acting on BAT have not been fully elucidated, 
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perturbation of heat production in BAT has the potential to reduce energy expenditure and therefore enhance 
the development of obesity.
Another major metabolic side-effect of GCs is disrupted glucose homeostasis. This has been well character-
ised in both human populations and model organisms (both mouse and rat) exposed to  GCs4, 15–18. It appears to 
be as a result of direct and indirect actions (via regulation of other hormones) at a number of sites. The direct 
actions of GCs on a range of peripheral tissues such as skeletal muscle, adipose tissue, liver and pancreas are 
well known to contribute to glucose intolerance and a reduction in insulin sensitivity (reviewed in Pasieka et al. 
 201619 and Rafacho et al.  201420).
GC action within the brain is also likely to contribute to the adverse effects on glucose and insulin metabo-
lism. In particular, GCs act on AgRP neurons within the hypothalamus, and there is a wide body of evidence 
demonstrating that AgRP plays a critical role in the control of energy  balance21–25. In addition, AgRP is also 
well-recognised to be able to affect metabolic function in peripheral organs (reviewed in Ruud et al.  201726). For 
example, acute activation of AgRP neurons, using an optogenetic approach, results in insulin  resistance27, and 
insulin receptor deletion from these neurons leads to improved glucose  homeostasis28. Furthermore, deletion of 
the metabolic flexibility regulating enzyme, carnitine acetyltransferase (Crat), in AgRP neurons increases liver 
 triglycerides29, demonstrating that manipulation of AgRP neurons can affect hepatic lipid dynamics.
We have previously reported that GC excess in male mice leads to hyperphagia, obesity and hyperinsulinae-
mia. This state is characterised by elevated Agrp mRNA and AgRP is known to be a potent orexigenic neuro-
peptide produced in the arcuate nucleus of the hypothalamus. Our previous studies have shown that deletion 
of AgRP only has a minimal effect on the metabolic phenotype observed when corticosterone (Cort) is given in 
drinking water to male  mice9. However, AgRP neurons also express other potent neuropeptides and transmitters, 
and other reports have clearly shown important roles for these neurons that are not dependent upon drive by 
AgRP peptides  alone22,30,31. To further investigate the role of these neurons in the development of GC-induced 
side effects, we studied the effects of GCs on food intake, adiposity, hepatic lipid balance and glucose homeostasis 
in male and female mice lacking GR on AgRP neurons. Our data demonstrate that AgRP neurons have a role in 
mediating the effects of GCs on hepatic steatosis and insulin homeostasis.
Results
GR is knocked down in AgRP neurons in AgRP‑GR KO mice. To generate mice with the glucocor-
ticoid receptor (GR; Nr3c1) deleted solely from AgRP neurons, we crossed  GRflox/flox with  AgRP-IRES-Cre mice 
to obtain  AgRP-IRES-Cre/+::GRflox/flox mice (hereinafter AgRP-GR KO). To show specificity of the knockdown, we 
amplified the GR NULL band in a range of tissues including cerebellum, hypothalamus, liver and skeletal muscle 
and found recombination only in the hypothalamus (Fig. 1a). To further demonstrate the knockdown of GR on 
AgRP neurons, we carried out dual immunofluorescence to identify co-localisation of AgRP and GR. We further 
crossed our AgRP-GR KO strain to a Rosa-26-eYFP line to visualise the AgRP neurons, as we have found com-
mercially available AgRP antibodies to be non-specific in the Agrp-null mice. In  AgRPCRE/+::ROSA26+/?::GR+/+ 
control mice, dual staining with eYFP marking AgRP neurons showed 95% co-localisation with GR and AgRP, 
and there was a 97% knockdown of GR in AgRP-GR KO mice (Fig. 1b). When the level of Nr3c1 mRNA expres-
sion in the whole hypothalamus was examined, no difference in expression was observed between control and 
AgRP-GR KO mice with or without 3 weeks corticosterone (Cort; 75 μg/ml) treatment (Fig. 1c) and both control 
and AgRP-GR KO mice demonstrated a decrease in GR expression with Cort treatment. Lastly, we investi-
gated GR activation using Tsc22d3 (glucocorticoid-induced leucine zipper; GILZ) as a marker. Cort treatment 
increased GILZ expression in the whole hypothalamus of control mice, but not in AgRP-GR KO mice (Fig. 1d).
We next assessed whether the expected peripheral effects of GCs were maintained in peripheral tissues of 
AgRP-GR KO mice after 3 weeks Cort treatment. GCs are recognised to cause atrophy of various tissues including 
the adrenal glands, spleen and skeletal muscle. A similar degree of loss of mass was observed in these tissues in 
both control and AgRP-GR KO mice (Supplemental Figure S1a–S1c). Additionally, Tsc22d3 mRNA expression 
was increased as expected in both liver and adipose tissue in control and AgRP-GR KO mice (Supplemental 
Figure S1d and S1e), demonstrating that GCs are still active in these peripheral tissues. Furthermore, both control 
and AgRP-GR KO mice treated with Cort had similar circulating corticosterone levels, sampled prior to stress 
influencing the endogenous corticosterone levels (Supplemental Figure S1f) and similar water intake [indicative 
of the amount of Cort administered) (Control Cort 129.7 ± 9.6 ml vs. KO Cort 144.3 ± 18.5 ml, P = ns)]. These 
results indicate that both genotypes of mice had similar exposure to GCs.
Delayed onset hyperphagia in Cort treated female AgRP‑GR KO mice. Previous studies have 
shown little effect on body weight and appetitive behaviours from loss of GR on AgRP neurons under chow and 
high fat diet  conditions32. However, we were interested in the direct effects of GCs acting on these neurons, so 
we treated male and female mice with Cort in drinking water for three weeks to assess the effect on the meta-
bolic phenotype of excess GCs acting on AgRP neurons. Cort treatment increased food intake in female control 
mice in the first 48 h, however this increased food intake was absent in AgRP-GR KO mice (Fig. 2a). Over three 
weeks, the female control mice maintained their Cort-induced hyperphagia (Fig. 2b) as shown previously in 
male C57Bl/6J mice. AgRP-GR KO mice, however, had delayed onset Cort-induced hyperphagia, but by day 10 
were eating a similar amount to Cort-treated control mice (Fig. 2b), suggesting that other neuronal populations 
are responsible for the sustained hyperphagic effect of Cort treatment.
Cort‑induced increases in Agrp expression are prevented in female AgRP‑GR KO mice. Given 
that in the AgRP-GR KO mice, GCs are not able to act directly on AgRP neurons, we investigated the potential 
effects on the neuropeptides expressed by this neuronal population after Cort treatment. After 2 days, the levels 
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of Agrp in whole hypothalami of AgRP-GR KO mice were significantly less than those in the control mice (Sup-
plemental Figure S2a). Cort treatment for 3 weeks increased Agrp mRNA expression in control female mice, but 
this increase did not occur when GR was deleted from AgRP neurons (Fig. 2c).
Cort treatment did not change the expression of either Npy or Pomc mRNA in control or AgRP-GR KO mice 
after 2 days (Supplemental Figure S2b and S2c). In addition, Cort treatment did not increase Npy (Fig. 2d) or 
decrease Pomc (Fig. 2e) in these groups at 3 weeks.
Despite the delayed onset of hyperphagia with Cort treatment, body weight increased by a similar trajectory 
over the three week study in female AgRP-GR KO and control mice (Fig. 2f), accompanied by a similar feed 
efficiency (Supplemental Figure S2d). Furthermore, terminal adipose tissue mass was similar between Cort 
treated control and AgRP-GR KO mice (Fig. 2g,h).
Figure 1.  GR is knocked down in AgRP neurons. (a) Recombination of the NULL band is only present in the 
hypothalamus of male AgRP-GR KO mice. (b) Representative image showing co-localisation of GR and eYFP 
(AgRP) in the arcuate nucleus of female control, but not female AgRP-GR KO mice. Graphical insert showing 
the percentage co-localisation of GR and AgRP. (c) Nr3c1 (GR) and (d) Tsc22d3 (GILZ) mRNA expression 
in the whole hypothalamus of vehicle and 3 week Cort treated female control and AgRP-GR KO mice. C: 
cerebellum, H: hypothalamus, B: brown adipose tissue, L: liver, M: skeletal muscle, S: subcutaneous adipose 
tissue. (a) n = 1, (b) n = 4, graphical representation of 18 sections per genotype, unpaired student’s t-test (c) and 
(d) n = 7–10, Mann–Whitney non-parametric t-tests. *P < 0.01, **P < 0.01 control vehicle versus Cort. ^P < 0.05 
KO vehicle versus KO Cort. >>>P < 0.001 control versus KO.
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Figure 2.  (a–h) Female AgRP-GR KO mice have delayed onset hyperphagia, but normal body weight gain 
with corticosterone (Cort) treatment. (a) 48 h, (b) 3 week food intake. (c) Agrp, (d) Npy and (e) Pomc mRNA 
expression in whole hypothalamus, (f) percent change in body weight, (g) mesenteric and (h) subcutaneous 
adipose tissue wet weight in female control and AgRP-GR KO mice treated with Cort in drinking water for 
3 weeks. (i–l) Male mice. (i) food intake, (j) Agrp and (k) Npy mRNA expression in whole hypothalamus and 
(l) percent change in body weight in male control and AgRP-GR KO mice treated with Cort in drinking water 
for 3 weeks. (a–h) n = 7–10, (i–l) n = 7–10. (a, b, f, g, h, i, l) Two-way ANOVA with Tukey Multiple Comparison 
test, (c, d, e, j, k) Mann–Whitney non-parametric t-tests. *P < 0.01, **P < 0.01, ***P < 0.001 control vehicle versus 
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Cort‑induced hyperphagia and obesity persists in male AgRP‑GR KO mice. Male control 
 (GRflox/flox) mice had elevated food intake, body weight and adiposity (Fig. 2i,l and Supplemental Figure S3) 
in response to Cort, which is a similar metabolic response to C57Bl/6J  mice9. However, male AgRP-GR KO 
mice, unlike female AgRP-GR KO mice, had no protection from early Cort-induced hyperphagia (Fig. 2i) and 
this was despite a much smaller increase in Agrp expression with Cort treatment compared to vehicle-treated 
mice (Fig. 2j). There was also decreased Npy expression between Cort-treated control and AgRP-GR KO mice 
(Fig. 2k). Furthermore, compared to their control counterparts, male AgRP-GR KO mice had similar weight 
gain (Fig.  2l), and increases in adiposity (Supplemental Figure S3a) and brown adipose tissue (BAT) weight 
(Supplemental Figure S3b) after 3 weeks Cort treatment. Interestingly, the liver weight of male AgRP-GR KO 
mice was not increased with Cort treatment (Supplemental Figure S3c).
Cort treatment modifies brown adipose tissue in both control and AgRP‑GR KO female 
mice. Activation of AgRP neurons can affect  BAT27 and GCs induce “whitening” of  BAT9, 14. In the present 
study, three weeks Cort treatment increased BAT weight, as expected, in control mice, and there was a similar 
increase in the weight of BAT in AgRP-GR KO mice (Supplemental Figure  S4a). We additionally examined 
whether there were any differences in genes involved in thermogenesis in BAT. Of the four genes we investigated 
(Ppargc1a, Ucp1, Prdm16 and Cidea), the change in expression in response to Cort was similar between control 
and AgRP-GR KO mice (Supplemental Figure S4b). This indicates that the Cort-induced changes in BAT weight 
are not mediated via AgRP neurons in female mice.
Female AgRP‑GR KO mice have less GC‑induced hepatic steatosis. Liver weight and fat deposi-
tion were increased with 3 weeks Cort treatment in female mice (Fig. 3a,c), as was also shown in their male 
littermates (Supplemental Figure S3c). Furthermore, in female, as in the male, AgRP-GR KO mice, there was 
no increase in liver weight with Cort treatment (Fig. 3a). Chronic Cort treatment also increased plasma tri-
glycerides in control mice at three weeks (Fig. 3b), but this was absent in AgRP-GR KO mice treated with Cort 
(Fig. 3b). In control mice, Cort also increased hepatic lipid content, as measured by Oil Red O (Fig. 3c,d) and 
liver triglycerides (Fig. 3e). This effect was less pronounced in AgRP-GR KO mice (Fig. 3c–e), giving a greater 
than 25% reduction in hepatic triglycerides compared to Cort-treated control mice (Fig. 3e).
To investigate the underlying mechanisms behind the improved plasma triglycerides and hepatic steatosis we 
examined the expression of some of the genes involved in lipid homeostasis in liver and subcutaneous (inguinal) 
adipose tissue. In liver, the expression of the fatty acid transporter, Cd36 was increased with Cort treatment in 
control, but not AgRP-GR KO mice (Fig. 3f). The mRNA expression of Atgl, a gene involved in lipolysis, was 
increased in Cort treated control, but not in AgRP-GR KO mice compared to their respective vehicle groups 
(Fig. 3g). There were no obvious changes in the gene expression of the regulators of de novo lipogenesis, between 
Cort-treated control and AgRP-GR KO mice (Fig. 3h).
In inguinal adipose tissue, the mRNA expression of Cd36 was increased similarly in both control and AgRP-
GR KO mice with Cort treatment (Fig. 3i), whereas the mRNA expression of Scd1, a gene involved in de novo 
lipogenesis, was increased in Cort-treated AgRP KO mice compared to Cort treated control mice (Fig. 3j). There 
were no significant increases in the mRNA expression of genes controlling lipolysis in either control or AgRP-
GR KO adipose tissue (Fig. 3k).
AgRP‑GR KO mice on Cort are less hyperinsulinaemic than control mice on Cort. To assess glu-
cose tolerance, an intraperitoneal glucose tolerance test (ipGTT) was carried out in a separate cohort of female 
mice treated with Cort for 10 days. Ten days of treatment was chosen as at this timepoint there was no difference 
between Cort-induced food intake (Fig. 2b) and body weight (Fig. 2f) between control and AgRP-GR KO mice. 
Cort treatment increased fasting insulin levels in both control and KO mice (Fig. 4a), but the effect was much 
greater in control animals suggesting that loss of GR on AgRP neurons decreases Cort-induced insulin resist-
ance.
During the ipGTT, this marked difference in degrees of Cort-induced hyperinsulinaemia between AgRP-
GR KO and control animals was maintained (Fig. 4b). Of note, throughout the GTT there was little change 
in the insulin levels in Cort treated AgRP-GR KO mice and although the mean levels of insulin in this group 
were around 5.8 fold higher than vehicle treated AgRP-GR KO animals, the difference did not reach statistical 
significance.
In terms of glucose there was no difference in fasting glucose before the ipGTT (Fig. 4c). Levels during the 
GTT, the most striking effect was driven by Cort treatment rather than genotype, with a significantly lower glu-
cose at 15 and 30 min seen in Cort treated animals of both genotypes compared to vehicle (Fig. 4d) leading to 
a reduction in AUC, which was more marked in AgRP-GR KO mice (Fig. 4e). Of note, glucose levels at 15 min 
in Cort treated AgRP-GR KO mice were lower than Cort-treated control mice, but this effect was not as great 
as the effect of genotype.
Despite this difference, increases in the expression of genes involved in gluconeogenesis in liver after 3 weeks 
on Cort were similar between control and AgRP-GR KO mice (Fig. 4f). There were also similar responses to 
Cort in the control and AgRP-GR KO mice for genes involved in insulin signalling in skeletal muscle and liver 
after 3 weeks on Cort (Fig. 4g,h).
Discussion
Chronic GC treatment can lead to many metabolic abnormalities. The present study has demonstrated that 
GCs acting on AgRP neurons contribute to the Cort-induced hyperinsulinaemia and hepatic steatosis in female 
mice. When these chronic effects of GCs on hypothalamic AgRP neurons are prevented in AgRP-GR KO mice, 
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:13776  | https://doi.org/10.1038/s41598-021-93378-3
www.nature.com/scientificreports/
Figure 3.  Female AgRP-GR KO mice are partially protected from corticosterone (Cort)-induced hepatic 
steatosis. (a) Liver weight, (b) plasma triglycerides, (c) representative images of Oil Red O staining, (d) 
quantification of Oil Red O staining, (e) liver triglycerides, mRNA expression in liver of (f) Cd36, a fatty acid 
transport gene, (g) lipolysis genes and (h) de novo lipogenesis genes. Adipose mRNA expression of (i) Cd36, a 
fatty acid transport gene, (j) de novo lipogenesis and (k) lipolysis genes. All mice were treated with vehicle or 
Cort in drinking for 3 weeks. (a) and (b) n = 7–10, Two-way ANOVA with Tukey Multiple Comparison test, 
(d) n = 7, 30 images per animal analysed, Two-way ANOVA with Tukey Multiple Comparison test. (e) n = 8–10, 
Two-way ANOVA with Tukey Multiple Comparison test, (f–k) n = 7–10, Mann–Whitney non-parametric 
t-tests. *P < 0.01, **P < 0.01, ***P < 0.001 control vehicle versus Cort, ^P < 0.05 KO vehicle versus Cort.
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Figure 4.  Female AgRP-GR KO mice are partially protected from corticosterone (Cort)-induced insulin 
resistance. (a) Fasting insulin following a 5 h day time fast in control and AgRP-GR KO mice treated with Cort 
for 10 days. (b) Insulin concentrations during an intraperitoneal glucose tolerance test (ipGTT) following 
10 days Cort treatment. (c) Fasting glucose, (d) glucose levels during an intraperitoneal glucose tolerance 
test (ipGTT), (e) area under the curve of the glucose ipGTT undertaken following 10 days Cort treatment, 
(f) mRNA expression of genes associated with gluconeogenesis in liver after 3 weeks Cort treatment. mRNA 
expression of genes associated with insulin resistance in (g) skeletal muscle and (h) liver. (f–h) Samples were 
taken from non-fasting animals (a) n = 8–10, (b) n = 8–9, (c–e) 8–10 Two-way ANOVA with Tukey Multiple 
Comparison test, (f–h) n = 7–10, Mann–Whitney non-parametric t-tests. *P < 0.01, ***P < 0.001 control vehicle 
versus Cort, ^P < 0.05, ^^P < 0.01 KO, ^^^P < 0.001 vehicle versus Cort, >P < 0.05, >>P > 0.01, >>>P > 0.001 control 
Cort versus KO Cort.
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there were changes in mRNA expression consistent with enhanced adipose tissue de novo lipogenesis, decreased 
transport of fatty acids into the liver and reduced hepatic de novo lipogenesis. It seems likely that these changes 
contribute to the reductions in hepatic steatosis and hyperinsulinaemia in the AgRP-GR KO mice. Addition-
ally, the knockdown of GR on AgRP neurons leads to delayed onset Cort-induced hyperphagia, but with time, 
hyperphagia prevailed and there was similar body weight gain and adiposity to that in Cort treated control mice.
We have previously developed a robust and reproducible model of GC excess in male  mice9–11. Here we 
characterised both male and female littermates and demonstrate a similar change in Cort-induced metabolic 
effects in female control  (GRflox/flox) mice. Female mice developed hyperphagia, with an increase in body weight, 
increased BAT weight, decreased expression of genes involved in thermogenesis, and increased glucose stimulated 
insulin release. It is notable that in Cort treated female mice there was much less glucose excursion and faster 
normalisation of glucose after an ip glucose bolus. We can only speculate upon the tissue responsible for the 
improved glucose effectiveness seen in this paradigm of fasting and Cort treatment, and further dynamic studies 
of carbon sources relevant to gluconeogenic substrates and lipid flux are required to fully understand this find-
ing. In keeping with the present study, previous studies using high dose Cort pellets also demonstrated a myriad 
of metabolic effects with Cort-treatment in female mice, but hyperglycaemia was also absent as well as a lower 
glucose excursion in female Cort treated mice during a GTT 33. A further study reported no metabolic effects of 
GCs in female CD1  mice34. This observation may be due to mouse strain differences and/or the administration 
of a lower dose of Cort (50 μg/ml).
One of the most robust effects observed with GC treatment is hyperphagia, which is associated with elevated 
Agrp mRNA  expression9,11,35,36. This effect would suggest that Cort treatment acts via increasing AgRP to cause 
elevated food intake, yet when AgRP is deleted globally, there is only a mild reduction in the GC induced 
 hyperphagia9. In the present study, where GCs are unable to act on the whole AgRP neuron (also containing NPY 
and GABA) there was delayed onset hyperphagia in the AgRP-GR KO mice and they did not display the large 
increase in Agrp mRNA expression with Cort treatment. The role of the AgRP neurons in hyperphagia is sup-
ported by many studies where activation of AgRP  neurons21,22 and increases in  AgRP37 or  NPY38 peptide levels are 
associated with hyperphagia in rodents. Conversely, AgRP neuron ablation in adult mice leads to  starvation39,40. 
The phenomenon of an acute increase in leptin and insulin after GC treatment is well  recognised9,41. Although 
both are considered to be anorexigenic drivers, the overall net integrated output in animals is still to drive hyper-
phagia. The mechanism underlying this dominant drive to eat remains to be determined.
The loss of GR from AgRP neurons afforded some protection from the Cort induced increase in food intake, 
at least in the earlier part of the study. However, this was not sufficient to reduce the Cort induced body weight 
gain and increases in adipose tissue mass measured at the end of the study. Though not measured in the present 
study, this is potentially due to changes in energy expenditure, as studies by another group have shown that 
female AgRP-GR KO mice have increased energy expenditure albeit on a high fat  diet32. However, we observed 
no difference in BAT weight or the mRNA expression of markers of thermogenesis between Cort-treated WT 
and AgRP-GR KO mice.
In the present study where GCs were not able to signal in AgRP neurons, we showed improved GC-induced 
GSIS and fasting hyperinsulinaemia suggesting increased insulin sensitivity compared to Cort treated control 
mice. This is in keeping with previous studies where activation of AgRP  neurons27 or overexpression of β-arrestin 
in these  neurons42 leads to insulin resistance. In contrast, ablation of the  neuron43 or modulation of intracellular 
signalling in AgRP  neurons29,42,44,45 improves insulin sensitivity. This may be due to the potential signalling from 
AgRP neurons to the  pancreas43. Equally, in a previous study, the deletion of purinergic receptor 6 (P2Y6) from 
AgRP neurons caused changes in AgRP neuronal inputs to the  liver44, suggesting that in our AgRP-GR KO mice, 
the improvement in insulin sensitivity could additionally be related to signalling to the liver, leading to the lower 
levels of hepatic steatosis.
In the present study we observed a decrease in Cort-induced hepatic steatosis. This reduction in steatosis 
could be mediated, at least in part, by reduced AgRP neuron activity signalling to peripheral tissues. The AgRP-
GR KO mice do not develop the elevated plasma triglycerides or liver weight on Cort and they have a reduction 
in hepatic lipids compared to control mice. Although previous studies on AgRP neurons have not investigated 
the effects of GCs, activation of AgRP neurons can affect substrate  utilisation23 and mediate changes in liver and 
adipose tissue. Plasma triglycerides are increased when AgRP neurons are  ablated43, whereas they are decreased 
when the enzyme, Crat, is deleted from AgRP neurons in mice on high fat  diet29. Furthermore, liver triglycer-
ides and hepatic lipid levels are increased when AgRP neurons are manipulated or  ablated29,42,43. Additionally, 
manipulation of AgRP neurons can alter the genes associated with de novo lipogenesis and lipolysis in  liver29,42,43. 
Moreover, manipulation of AgRP neurons has effects on adipose tissue  lipolysis23,29,46, that could increase the 
availability of fatty acids for uptake into the liver in the Cort-treated control mice and this would be reduced in 
the AgRP-GR KO mice. Taken together these mechanisms may explain how the peripheral effects on lipid bal-
ance in AgRP-GR KO mice could be mediated by direct effects of AgRP neurons.
In conclusion, the knockdown of GR on AgRP neurons causes attenuation of the GC-induced increases in 
plasma and liver triglycerides, and partially prevents GC-induced hyperinsulinaemia and insulin signalling 
abnormalities in female mice. It also delayed the Cort-induced hyperphagia. This highlights the need to build 
an understanding of the role of chronic GCs acting on AgRP neurons which, at least in part, leads to the GC-
induced hyperinsulinaemia and hepatic steatosis.
Methods and materials
Generation of genetically modified mice. All mice were bred in house at the University of Manches-
ter, Manchester, UK. To generate mice with the glucocorticoid receptor (GR; Nr3c1) deleted solely from AgRP 
neurons we crossed  GRflox/flox (B6.129P2-Nr3c1tm2Gcs/Ieg EMMA strain #02124) with  AgRP-IRES-Cre mice 
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 (Agrptm1(cre)Lowl/J Jackson strain #012899) to obtain  AgRP-IRES-Cre/+::GRflox/flox mice (hereinafter AgRP-GR KO), 
where GR was deleted solely from AgRP neurons. To fluorescently mark the AgRP neurons with eYFP, the 
AgRP-GR KO mice were crossed with R26-stop-eYFP mice (B6.129X1-GT(ROSA)26Sortm1(EYFP)Cos/J Jackson 
stain #006148).
To genotype the mice, DNA was extracted from ear snips and mice were genotyped using the following 
primers: GR Flox: forward: 5′-GGC ATG CAC ATT ACT GGC CTT CT-3′, reverse 4 (NULL band) 5′-GTG 
TAG CAG CCA GCT TAC AGG A-3′ and reverse 8 (WT/Flox) 5′-CCT TCT CAT TCC ATG TCA GCA TGT-3′, 
giving product sizes of WT—225 bp, Flox—275 bp and NULL—390 bp. AgRP-Cre: common forward primer 
(12638) 5′-GCT TCT TCA ATG CCT TTT CG-3′, internal positive control (IPC) reverse primer (12639) 5′-GTG 
TGT GGT TCC AGC ATG AC-3′, and mutant reverse primer (12640) was 5′-AGG AAC TGC TTC CTT CAC 
GA-3′, giving an IPC product size of 199 bp in all mice and a mutant product size of 280 bp in the mice positive 
for Cre. ROSA26 genotyping used separate reactions for wild-type and mutant assays. The wild-type primers 
were forward (21306) 5′-CTG GCT TCT GAG GAC CG-3′ and reverse (24500) 5′-CAG GAC AAC GCC CAC 
ACA-3′ giving a product size of 142 bp. The mutant assay forward primer (24951) was 5′-AGG GCG AGG AGC 
TGT TCA-3′ and the reverse primer (24952) was 5′-TGA AGT CGA TGC CCT TCA G-3′ giving a product size 
of 384 bp. Heterozygous (Het) mice had a positive band in both the wild-type and the mutant assay.
Study design. A total of 240 AgRP-GR KO mice and their control  (GRflox/flox) littermate mice were used in 
these studies, with no deaths during the studies.  AgRP-IRES-Cre mice have been previously shown not to have a 
phenotype and were therefore not included as a control  strain42. All mice were maintained on a 12:12 light cycle 
(lights on at 7 a.m. and lights off at 7 p.m.) in specific pathogen-free cages with wood chip bedding and envi-
ronmental enrichment in an ambient temperature of 23 ± 1 °C. Food and water were available ad libitum, except 
where food was removed for fasting.
Nine to eleven week old mice were singly housed and acclimatised for 1 week, prior to a 2 week baseline 
during which food and water intake were monitored twice weekly. Mice were randomly assigned at genotyping 
to treatment group, either corticosterone (Cort; Sigma-Aldrich, 27840-500MG or Caymen Chemicals, 16063-
500 mg-CAY both > 98% purity at 75 μg/ml in 1% ethanol) or vehicle (1% ethanol) in drinking water as in previ-
ous  studies9–11. Animals were randomly assigned to the cage rack and were randomly moved during the course 
of the study. This prevented bias due to rack position. Three cohorts of mice were used. Male and female mice 
were treated for 21 days (main study), or female mice were treated for 48 h to investigate acute food intake and a 
further sub-group were treated for use in the ipGTT after 10 days treatment. All cohorts had a group size of 10. 
This was based on previous studies in a different strain of transgenic mice and accounted for the additional vari-
ability that we have previously observed with transgenic strains. In this study we powered based on a detectable 
change in body weight of 3.5 g, with a SD of 2.75. Using a group size of 10 gives us a power of 81.2. In the 21 day 
study, mice were tail bled for corticosterone prior to euthanasia by rising  CO2 followed by exsanguination. Tissues 
were weighed and then snap frozen on dry ice, placed in RNAlater (Sigma, R0901), or placed in 10% formalin 
as appropriate. During the in-life measurements, researchers were blinded to the genotype of the animal, but 
the treatment was visible. Any samples taken from the mice were assigned a study number and from this point 
all measurements were fully blinded.
All experiments were performed in accordance with the UK Home Office legislation [Animal (Scientific 
Procedures) Act 1986], were approved by the University of Manchester local ethics committee and comply with 
the ARRIVE guidelines.
Biochemical measurements. Glucose and insulin were measured fresh in tail-prick blood samples using 
a glucometer (Accu-Chek, Roche) and an ELISA (Crystal Chem, 90080) respectively. For corticosterone, blood 
samples were taken within one minute of disturbing the cage by tail-prick sample. Samples were then centri-
fuged, and the plasma frozen at − 80 °C for later analysis by ELISA (corticosterone, Abnova, KA0468). Triglyc-
erides were measured using a colourimetric assay (Sigma, F6428 and T2449). This was carried out using plasma 
samples taken by cardiac puncture at the end of the study or frozen liver samples which were homogenised in 
propan-2-ol with Triton-X.
Identification of the GR Flox null band in tissues. Mice were culled by rising  CO2 and various tissues 
were snap frozen on dry ice. Genomic DNA (gDNA) was extracted from these tissues, the NULL band was 
amplified and visualised. The presence of a band indicates recombination, and therefore deletion, in that tissue. 
The primers were forward 5′-GGC ATG CAC ATT ACT GGC CTT CT-3′ and reverse (NULL) 5′-GTG TAG 
CAG CCA GCT TAC AGG A-3′. GAPDH was used as a loading control with forward 5′-AAC GAC CCC TTC 
ATT GA-3′ and reverse 5′-TCC ACG ACA TAC TCA GCA C-3′ primers. Samples were run on a 2% agarose gel 
and the GR NULL PCR gave a band of 390 bp and GAPDH 190 bp.
Dual immunofluorescence for GR and AgRP (eYFP). Female  AgRPCRE/+::Rosa26+/?::GR−/− (AgRP-GR 
KO x Rosa eYFP) mice and their  AgRPCRE/+::Rosa26+/?::GR+/+ (GR WT Rosa eYFP) littermates were culled by 
rising  CO2. Whole brains were dissected and placed into 4% paraformaldehyde for 24 h followed by 30% sucrose 
for 24–48 h as appropriate and rapidly frozen on dry ice. Brains were stored at − 80 °C until sectioning on a 
freezing microtome, where 25  μm sections were taken. Free-floating sections were washed in PBS-T before 
being permeabilised in 0.25% Triton-X. Tissues were incubated in 1% SDS then blocked in 5% goat serum with 
0.5% BSA and 0.25% Triton-X for 1 h at room temperature. Sections were co-incubated with 1:5000 anti-GFP 
(Abcam, ab13970) and 1:300 Anti-GR (Proteintech, 24050-I-AP) primary antibodies for 3 h at room tempera-
ture followed by overnight at 4 °C. After PBS washes, sections were incubated with 1:400 goat anti-rabbit 594 
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(Life Technologies, A11037) and 1:400 goat anti-chicken 488 (Life Technologies, A11039) secondary antibodies 
in 5% goat serum, 0.5% BSA and 0.25% Triton-X for 2 h and 15 min at room temperature. Sections were washed 
in PBS followed by water, added to slides and dried before being mounted in Prolong Gold AntiFade mountant 
containing DAPI (Thermo Fisher, 11569306) and coverslipped.
Images were collected on a Zeiss Axioimager.D2 upright microscope using a 10×/EC Plan-neofluor objective 
and captured using a Coolsnap HQ2 camera (Photometrics) through Micromanager software v1.4.23. Images 
were then processed using ImageJ software (www. imagej. net). Four mice per genotype were stained and three 
to five sections per brain examined, leading to 18 sections per genotype being quantified for co-localisation of 
GR and eYFP.
Real‑time quantitative PCR. RT-qPCR was carried out as previously described in Sefton et  al.  20199. 
Briefly, RNA was extracted using an RNeasy Mini Kit (Qiagen, 74104) with on-column genomic DNA digestion, 
with an additional phenol extraction for adipose tissue. RNA was quantified using a Nanodrop-2000 spectro-
photometer and was reverse transcribed using the High Capacity cDNA RT kit (Applied Biosystems, 4368814). 
Transcript levels were determined using a Prism 7900HT (Applied Biosystems) with either Universal Master 
Mix II (TaqMan; Applied Biosystems, 4440043) or Go Taq qPCR Master Mix (SYBR; Promega, A6010). TaqMan 
catalogue numbers and primer sequences are listed in Supplemental Tables 1 and 2. Samples were quantified 
using a standard curve with HPRT or TBP for TaqMan or SYBR assays, respectively, as reference genes, and the 
WT vehicle group as calibrator.
Immunohistochemistry. Livers were fixed in formalin for 24 h, cryoprotected in 30% sucrose for 24 h and 
frozen in OCT using supercooled 2-methylbutane, and stored at − 80 °C. Livers were sectioned at 12 μm and 
were taken at 3 depths through the tissue. Slides were frozen at − 80 °C prior to staining. Hemotoxylin & eosin 
staining was performed as  before9. For Oil Red O staining, slides were incubated with Oil Red O (Sigma, CI 
26125) without a counterstain, prior to mounting and cover slipping.
All images were visualised using a 20×/0.80 Plan Apo objective using a 3D-Histech Panoramic-250 Flash II 
slide scanner (3D Histech, Hungary). Snapshots of the slide scans were taken using CaseViewer software (3D 
Histech).
Oil Red O staining was quantified using ImageJ software. Ten fields of view per section (30 fields of view per 
animal) were analysed to give one value per mouse.
Intraperitoneal glucose tolerance test. Mice were given Cort in drinking water for 10  days before 
undergoing an intraperitoneal glucose tolerance test (ipGTT). Food was removed and mice were placed in clean 
cages at 8am for a 5 h fast. Before the ipGTT mice were weighed and had a T = 0 blood sample taken by tail-prick 
microsampling for glucose (blood droplet, Accu-Chek) and insulin (5 μl blood, ELISA, Crystal Chem, 90,080). 
Mice were given an ip injection of 20% glucose (2  g/kg fasted body weight). Further samples were taken at 
T = 15 min and T = 30 min post glucose for glucose and insulin and T = 60 min and T = 120 min for glucose only.
Statistical analysis. The data were analysed using Prism 8.0 (GraphPad) and are presented as mean ± S.E.M. 
For normally distributed data, Student’s t-test was performed between two groups and a two-way ANOVA 
between multiple groups. For non-normally distributed data (including real-time quantitative PCR data), the 
groups were compared by Mann–Whitney U test. P values of 0.05 were considered to indicate statistical sig-
nificance. Samples that were 2 SD ± mean were removed as statistical outliers which was decided prior to the 
commencement of the study.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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